for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

XOMA Corp

XOMA.OQ

Latest Trade

20.00USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

11.10

 - 

22.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
20.00
Open
--
Volume
--
3M AVG Volume
1.50
Today's High
--
Today's Low
--
52 Week High
22.00
52 Week Low
11.10
Shares Out (MIL)
8.73
Market Cap (MIL)
174.55
Forward P/E
-17.33
Dividend (Yield %)
--

Next Event

XOMA Corp Annual Shareholders Meeting

Latest Developments

More

XOMA Reports Second Quarter 2019 Royalty Asset Portfolio Highlights And Financial Results

XOMA Reports Q1 Revenue Of $8.1 Million Versus $500,000

XOMA Acquires Royalty Rights To Five Hematology Candidates

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About XOMA Corp

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Industry

Biotechnology & Drugs

Contact Info

2200 Powell St Ste 310

+1.510.2047239

http://www.xoma.com/

Executive Leadership

W. Denman Van Ness

Lead Independent Chairman of the Board

James R. Neal

Chief Executive Officer, Chief Operating Officer, Director

William Irwin Garrard

Chief Financial Officer, Vice President - Finance

Danny Hart

Vice President, General Counsel

Barbara A. Kosacz

Director

Key Stats

2.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.1K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-8.890

2017

0.730

2018

-1.590

2019(E)

-1.154
Price To Earnings (TTM)
--
Price To Sales (TTM)
14.95
Price To Book (MRQ)
8.32
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
123.97
LT Debt To Equity (MRQ)
111.22
Return on Investment (TTM)
-16.10
Return on Equity (TTM)
-14.10

Latest News

BRIEF-XOMA Reports Qtrly Loss Per Share $0.46

* QTRLY LOSS PER SHARE $0.46 Source text for Eikon: Further company coverage:

BRIEF-Xoma Corp - Entered Loan And Security Agreement Of Up To $20.0 Million

* XOMA CORP - CO, UNITS ENTERED LOAN AND SECURITY AGREEMENT UNDER WHICH LENDER AGREED TO LEND UP TO $20.0 MILLION IN A SERIES OF TERM LOANS - SEC FILING

BRIEF-Xoma Announces $20 Mln Credit Facility With Silicon Valley Bank To Advance Royalty-Aggregator Business Model

* XOMA ANNOUNCES $20 MILLION CREDIT FACILITY WITH SILICON VALLEY BANK TO ADVANCE ROYALTY-AGGREGATOR BUSINESS MODEL Source text for Eikon:

BRIEF-Xoma Corp Says Amended License And Purchase Agreement Entered With Rezolute In Dec 2017

* XOMA CORP SAYS ON MARCH 30, CO AMENDED LICENSE AGREEMENT AND PURCHASE AGREEMENT ENTERED INTO WITH REZOLUTE IN DEC 2017 - SEC FILING Source text: (https://bit.ly/2GCCEuu) Further company coverage:

BRIEF-Xoma Corp Files For Mixed Shelf Of Up To $300 Million

* XOMA CORP FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILING Source text (http://bit.ly/2D8ZcQW) Further company coverage:

BRIEF-Xoma Reports Q4 Loss Per Share $0.16

* XOMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-XOMA Announces Exclusive License Agreement For XOMA 358 With Rezolute Inc.

* XOMA ANNOUNCES EXCLUSIVE LICENSE AGREEMENT FOR XOMA 358 WITH REZOLUTE, INC.

BRIEF-Xoma posts Q3 revenue of $36.2 million

* Qtrly diluted net income per share available to common stockholders $1.98 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-XOMA ANNOUNCES MULTIPLE NEW LICENSE AGREEMENTS FOR PROPRIETARY PHAGE DISPLAY LIBRARIES

* XOMA ANNOUNCES MULTIPLE NEW LICENSE AGREEMENTS FOR PROPRIETARY PHAGE DISPLAY LIBRARIES

BRIEF-XOMA Earns $3 million milestone payment from its license agreement with Nanotherapeutics

* XOMA earns $3 million milestone payment from its license agreement with nanotherapeutics Source text for Eikon: Further company coverage: [XOMA.O ]

BRIEF-Novartis Pharma reports a 6.6 percent passive stake in Xoma Corp as of August 24, 2017

* Novartis Pharma AG reports a 6.6 percent passive stake in Xoma Corp as of august 24, 2017 - SEC filing Source text for Eikon: (http://bit.ly/2gEet2Y) Further company coverage:

BRIEF-Xoma announces transformational license agreements for gevokizumab and its IL-1 beta intellectual property portfolio

* Xoma announces transformational license agreements for gevokizumab and its IL-1 beta intellectual property portfolio

BRIEF-XOMA earns $10 mln milestone payment as a licensed asset advances into clinical development

* XOMA earns $10 million milestone payment as another of its licensed assets advances into clinical development Source text for Eikon:

BRIEF-Xoma Q1 loss per share $2.37

* Q1 basic and diluted net loss per share available to common shareholders of $2.37

BRIEF-Xoma announces positive results from its phase 2 study of prolactin inhibition

* Xoma announces positive results from its phase 2 proof-of-concept study of prolactin inhibition

BRIEF-Xoma receieves notice to terminate license agreement from Novo Nordisk

* Xoma -on april 20, 2017 co received notice from Novo Nordisk a/s, relating to termination of exclusive license agreement with co due to strategic and business reasons

BRIEF-Xoma presents positive data from PTH1R monoclonal antibody program

* Xoma presents positive data from PTH1R monoclonal antibody program

BRIEF-Xoma announces full repayment of Hercules Technology Growth Capital debt obligation

* Xoma announces full repayment of hercules technology growth capital debt obligation

BRIEF-Xoma board approved salary increases for CEO James Neal, CFO Thomas Burns on March 2, 2017

* Xoma -on March 2, 2017, board approved salary increases for James Neal, chief executive officer, and Thomas Burns, chief financial officer Source text (http://bit.ly/2mkguDP) Further company coverage:

BRIEF-Xoma Corp to sell 1.2 mln shares to Biotechnology Value Fund

* Xoma announces pricing of $25 million registered offering of common stock and convertible preferred stock

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up